

Romina Mizrahi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/798147/publications.pdf>

Version: 2024-02-01

143
papers

8,046
citations

44069

48
h-index

53230

85
g-index

147
all docs

147
docs citations

147
times ranked

9570
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of Translocator Protein Density, a Marker of Neuroinflammation, in the Brain During Major Depressive Episodes. <i>JAMA Psychiatry</i> , 2015, 72, 268.	11.0	700
2	From dopamine to salience to psychosisâ€”linking biology, pharmacology and phenomenology of psychosis. <i>Schizophrenia Research</i> , 2005, 79, 59-68.	2.0	433
3	Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review. <i>Molecular Psychiatry</i> , 2016, 21, 1009-1026.	7.9	272
4	A prospective longitudinal study of apathy in Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 8-11.	1.9	270
5	Differential Effects of Aripiprazole on D ₂ , 5-HT ₂ , and 5-HT _{1A} Receptor Occupancy in Patients With Schizophrenia: A Triple Tracer PET Study. <i>American Journal of Psychiatry</i> , 2007, 164, 1411-1417.	7.2	235
6	The Construct of Minor and Major Depression in Alzheimerâ€™s Disease. <i>American Journal of Psychiatry</i> , 2005, 162, 2086-2093.	7.2	230
7	Increased Stress-Induced Dopamine Release in Psychosis. <i>Biological Psychiatry</i> , 2012, 71, 561-567.	1.3	222
8	On the overlap between apathy and depression in dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 1070-1074.	1.9	204
9	Association of translocator protein total distribution volume with duration of untreated major depressive disorder: a cross-sectional study. <i>Lancet Psychiatry</i> , the, 2018, 5, 339-347.	7.4	192
10	A diagnostic formulation for anosognosia in Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 719-725.	1.9	190
11	Imaging Neuroinflammation in Gray and White Matter in Schizophrenia: An In-Vivo PET Study With [18F]-FEPPA. <i>Schizophrenia Bulletin</i> , 2015, 41, 85-93.	4.3	158
12	White matter hyperintensities are significantly associated with cortical atrophy in Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004, 75, 822-827.	1.9	146
13	Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. <i>Journal of Neurochemistry</i> , 2006, 97, 1089-1103.	3.9	145
14	Adverse Subjective Experience With Antipsychotics and Its Relationship to Striatal and Extrastriatal D ₂ Receptors: a PET Study in Schizophrenia. <i>American Journal of Psychiatry</i> , 2007, 164, 630-637.	7.2	141
15	Inflammation in the Neurocircuitry of Obsessive-Compulsive Disorder. <i>JAMA Psychiatry</i> , 2017, 74, 833.	11.0	132
16	Translocator Protein (18â€%kDa) Polymorphism (rs6971) Explains <i>in-vivo</i> Brain Binding Affinity of the PET Radioligand [¹⁸ F]-FEPPA. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 968-972.	4.3	131
17	Neuroinflammation and Oxidative Stress in Psychosis and Psychosis Risk. <i>International Journal of Molecular Sciences</i> , 2017, 18, 651.	4.1	124
18	Insight and danger in Alzheimer's disease. <i>European Journal of Neurology</i> , 2007, 14, 455-460.	3.3	114

#	ARTICLE	IF	CITATIONS
19	The Dopamine D2 Receptors in High-Affinity State and D3 Receptors in Schizophrenia: A Clinical [¹¹ C]-(+)-PHNO PET Study. <i>Neuropsychopharmacology</i> , 2009, 34, 1078-1086.	5.4	109
20	Neuroimaging Correlates of Apathy and Depression in Alzheimer's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2009, 21, 259-265.	1.8	103
21	Imaging Microglial Activation in Untreated First-Episode Psychosis: A PET Study With [¹⁸ F]FEPPA. <i>American Journal of Psychiatry</i> , 2017, 174, 118-124.	7.2	103
22	Positron Emission Tomography Studies of the Glial Cell Marker Translocator Protein in Patients With Psychosis: A Meta-analysis Using Individual Participant Data. <i>Biological Psychiatry</i> , 2018, 84, 433-442.	1.3	103
23	In-vivo imaging of grey and white matter neuroinflammation in Alzheimer's disease: a positron emission tomography study with a novel radioligand, [¹⁸ F]-FEPPA. <i>Molecular Psychiatry</i> , 2015, 20, 1579-1587.	7.9	101
24	Quantitation of Translocator Protein Binding in Human Brain with the Novel Radioligand [¹⁸ F]-FEPPA and Positron Emission Tomography. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011, 31, 1807-1816.	4.3	98
25	"Jumping to conclusions" and delusions in psychosis: Relationship and response to treatment. <i>Schizophrenia Research</i> , 2008, 98, 225-231.	2.0	97
26	The Effect of Antipsychotics on the High-Affinity State of D2 and D3 Receptors. <i>Archives of General Psychiatry</i> , 2009, 66, 606.	12.3	97
27	Brain region binding of the D2/3 agonist [¹¹ C]-(+)-PHNO and the D2/3 antagonist [¹¹ C]raclopride in healthy humans. <i>Human Brain Mapping</i> , 2008, 29, 400-410.	3.6	95
28	Imaging Striatal Microglial Activation in Patients with Parkinson's Disease. <i>PLoS ONE</i> , 2015, 10, e0138721.	2.5	95
29	Depression in Alzheimer's disease: Phenomenology, clinical correlates and treatment. <i>International Review of Psychiatry</i> , 2008, 20, 382-388.	2.8	90
30	Stress-Induced Dopamine Response in Subjects at Clinical High Risk for Schizophrenia with and without Concurrent Cannabis Use. <i>Neuropsychopharmacology</i> , 2014, 39, 1479-1489.	5.4	86
31	Kinetic Modeling of the Monoamine Oxidase B Radioligand [¹¹ C]SL25.1188 in Human Brain with High-Resolution Positron Emission Tomography. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 883-889.	4.3	83
32	Social Stress and Psychosis Risk: Common Neurochemical Substrates?. <i>Neuropsychopharmacology</i> , 2016, 41, 666-674.	5.4	79
33	Effects of antipsychotics on D3 receptors: A clinical PET study in first episode antipsychotic naive patients with schizophrenia using [¹¹ C]-(+)-PHNO. <i>Schizophrenia Research</i> , 2011, 131, 63-68.	2.0	78
34	How antipsychotics work? From receptors to reality. <i>NeuroRx</i> , 2006, 3, 10-21.	6.0	77
35	Molecular imaging of neuroinflammation in Alzheimer's disease and mild cognitive impairment. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 80, 123-131.	4.8	76
36	Monoamine Oxidase B Total Distribution Volume in the Prefrontal Cortex of Major Depressive Disorder. <i>JAMA Psychiatry</i> , 2019, 76, 634.	11.0	74

#	ARTICLE	IF	CITATIONS
37	Association of Structural Magnetic Resonance Imaging Measures With Psychosis Onset in Individuals at Clinical High Risk for Developing Psychosis. <i>JAMA Psychiatry</i> , 2021, 78, 753.	11.0	74
38	Correspondences between theory of mind, jumping to conclusions, neuropsychological measures and the symptoms of schizophrenia. <i>Psychiatry Research</i> , 2009, 170, 119-123.	3.3	72
39	Heterogeneity of Striatal Dopamine Function in Schizophrenia: Meta-analysis of Variance. <i>Biological Psychiatry</i> , 2020, 87, 215-224.	1.3	69
40	Mapping Human Brain Fatty Acid Amide Hydrolase Activity with PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 407-414.	4.3	65
41	The effect of antipsychotic treatment on Theory of Mind. <i>Psychological Medicine</i> , 2007, 37, 595.	4.5	64
42	Depression in Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 887-895.	2.8	58
43	The Fatty Acid Amide Hydrolase C385A Variant Affects Brain Binding of the Positron Emission Tomography Tracer [¹¹ C]CURB. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 1237-1240.	4.3	58
44	Neuroinflammation in healthy aging: A PET study using a novel Translocator Protein 18kDa (TSPO) radioligand, [18F]-FEPPA. <i>NeuroImage</i> , 2014, 84, 868-875.	4.2	56
45	Towards Precision Medicine in Psychosis: Benefits and Challenges of Multimodal Multicenter Studies—PSYSCAN: Translating Neuroimaging Findings From Research into Clinical Practice. <i>Schizophrenia Bulletin</i> , 2020, 46, 432-441.	4.3	56
46	Antidepressant therapy in post-stroke depression. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1291-1298.	1.8	55
47	Disrupted Nodal and Hub Organization Account for Brain Network Abnormalities in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 259.	3.4	53
48	Fatty Acid Amide Hydrolase Binding in Brain of Cannabis Users: Imaging With the Novel Radiotracer [11C]CURB. <i>Biological Psychiatry</i> , 2016, 80, 691-701.	1.3	53
49	The selective effect of antipsychotics on the different dimensions of the experience of psychosis in schizophrenia spectrum disorders. <i>Schizophrenia Research</i> , 2006, 88, 111-118.	2.0	52
50	The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 715.	2.1	52
51	Imaging Microglial Activation in Individuals at Clinical High Risk for Psychosis: an In Vivo PET Study with [18F]FEPPA. <i>Neuropsychopharmacology</i> , 2017, 42, 2474-2481.	5.4	47
52	Dopamine Response to Psychosocial Stress in Chronic Cannabis Users: A PET Study With [11C]-(+)-PHNO. <i>Neuropsychopharmacology</i> , 2013, 38, 673-682.	5.4	45
53	Elevated Striatal Dopamine Function in Immigrants and Their Children: A Risk Mechanism for Psychosis. <i>Schizophrenia Bulletin</i> , 2017, 43, sbw181.	4.3	44
54	Phenomenology and Clinical Correlates of Delusions in Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2006, 14, 573-581.	1.2	41

#	ARTICLE	IF	CITATIONS
55	Imaging changes associated with cognitive abnormalities in Parkinson's disease. <i>Brain Structure and Function</i> , 2015, 220, 2249-2261.	2.3	41
56	Impaired Prefrontal Cortical Dopamine Release in Schizophrenia During a Cognitive Task: A [11C]FLB 457 Positron Emission Tomography Study. <i>Schizophrenia Bulletin</i> , 2019, 45, 670-679.	4.3	39
57	The four dimensions: a model for the social aetiology of psychosis. <i>British Journal of Psychiatry</i> , 2011, 199, 11-14.	2.8	37
58	Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naïve patients and healthy controls while performing a cognitive task. <i>Journal of Psychiatry and Neuroscience</i> , 2013, 38, 98-106.	2.4	36
59	Event-Related Potentials in the Clinical High-Risk (CHR) State for Psychosis: A Systematic Review. <i>Clinical EEG and Neuroscience</i> , 2018, 49, 215-225.	1.7	36
60	Meta-analysis of the Glial Marker TSPO in Psychosis Revisited: Reconciling Inconclusive Findings of Patient-Control Differences. <i>Biological Psychiatry</i> , 2021, 89, e5-e8.	1.3	36
61	In Vivo Imaging of Translocator Protein in Long-term Cannabis Users. <i>JAMA Psychiatry</i> , 2019, 76, 1305.	11.0	34
62	Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis. <i>Neuropsychopharmacology</i> , 2018, 43, 2249-2255.	5.4	33
63	A systematic review of phytocannabinoid exposure on the endocannabinoid system: Implications for psychosis. <i>European Neuropsychopharmacology</i> , 2019, 29, 330-348.	0.7	33
64	Cortical stress regulation is disrupted in schizophrenia but not in clinical high risk for psychosis. <i>Brain</i> , 2018, 141, 2213-2224.	7.6	32
65	Relationships between cognitive event-related brain potential measures in patients at clinical high risk for psychosis. <i>Schizophrenia Research</i> , 2020, 226, 84-94.	2.0	31
66	Specificity of Symptoms of Depression in Alzheimer Disease: A Longitudinal Analysis. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 802-807.	1.2	30
67	How antipsychotics work: The patients' perspective. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 859-864.	4.8	30
68	Attribution style as a factor in psychosis and symptom resolution. <i>Schizophrenia Research</i> , 2008, 104, 220-227.	2.0	30
69	Imaging microglial activation and amyloid burden in amnesic mild cognitive impairment. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 1885-1895.	4.3	29
70	Endocannabinoid system in psychotic and mood disorders, a review of human studies. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 106, 110096.	4.8	29
71	The prevalence, clinical correlates and treatment of apathy in Alzheimer's disease. <i>European Journal of Psychiatry</i> , 2006, 20, .	1.3	29
72	Blocking of Fatty Acid Amide Hydrolase Activity with PF-04457845 in Human Brain: A Positron Emission Tomography Study with the Novel Radioligand [¹¹ C]CURB. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 1827-1835.	4.3	28

#	ARTICLE	IF	CITATIONS
73	Glutathione, the Major Redox Regulator, in the Prefrontal Cortex of Individuals at Clinical High Risk for Psychosis. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 311-318.	2.1	28
74	Dopamine response to psychosocial stress in humans and its relationship to individual differences in personality traits. <i>Journal of Psychiatric Research</i> , 2012, 46, 890-897.	3.1	26
75	Nigral Stress-Induced Dopamine Release in Clinical High Risk and Antipsychotic-Naïve Schizophrenia. <i>Schizophrenia Bulletin</i> , 2018, 44, 542-551.	4.3	26
76	GABA levels and TSPO expression in people at clinical high risk for psychosis and healthy volunteers: a PET-MRS study. <i>Journal of Psychiatry and Neuroscience</i> , 2019, 44, 111-119.	2.4	26
77	Evaluation of a novel radiotracer for positron emission tomography imaging of reactive oxygen species in the central nervous system. <i>Nuclear Medicine and Biology</i> , 2017, 53, 14-20.	0.6	25
78	Human Kinetic Modeling of the 5HT ₆ PET Radioligand ¹¹ C-GSK215083 and Its Utility for Determining Occupancy at Both 5HT ₆ and 5HT _{2A} Receptors by SB742457 as a Potential Therapeutic Mechanism of Action in Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1901-1909.	5.0	24
79	Mechanisms contributing to cognitive deficits in cannabis users. <i>Neuropharmacology</i> , 2017, 124, 84-88.	4.1	24
80	Whole Body Biodistribution and Radiation Dosimetry in Humans of a New PET Ligand, [18F]-FEPPA, to Image Translocator Protein (18kDa). <i>Molecular Imaging and Biology</i> , 2013, 15, 353-359.	2.6	23
81	Mitochondrial function in individuals at clinical high risk for psychosis. <i>Scientific Reports</i> , 2018, 8, 6216.	3.3	23
82	Elevated fatty acid amide hydrolase in the prefrontal cortex of borderline personality disorder: a [11C]CURB positron emission tomography study. <i>Neuropsychopharmacology</i> , 2020, 45, 1834-1841.	5.4	23
83	Specificity of Symptoms of Depression in Alzheimer Disease: A Longitudinal Analysis. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 802-807.	1.2	23
84	Interaction between TSPO—a neuroimmune marker—and redox status in clinical high risk for psychosis: a PET-MRS study. <i>Neuropsychopharmacology</i> , 2018, 43, 1700-1705.	5.4	22
85	A systematic review of the role of the nociceptin receptor system in stress, cognition, and reward: relevance to schizophrenia. <i>Translational Psychiatry</i> , 2018, 8, 38.	4.8	22
86	Fatty acid amide hydrolase is lower in young cannabis users. <i>Addiction Biology</i> , 2021, 26, e12872.	2.6	21
87	Corticotropin-releasing hormone and dopamine release in healthy individuals. <i>Psychoneuroendocrinology</i> , 2017, 76, 192-196.	2.7	20
88	Feasibility study of TSPO quantification with [18F]FEPPA using population-based input function. <i>PLoS ONE</i> , 2017, 12, e0177785.	2.5	20
89	Side Effects Profile in Humans of ¹¹ C-(+)-PHNO, a Dopamine D _{2/3} Agonist Ligand for PET. <i>Journal of Nuclear Medicine</i> , 2010, 51, 496-497.	5.0	19
90	Peripheral cytokine and fatty acid associations with neuroinflammation in AD and aMCI patients: An exploratory study. <i>Brain, Behavior, and Immunity</i> , 2020, 87, 679-688.	4.1	19

#	ARTICLE	IF	CITATIONS
91	Imaging Brain Fatty Acid Amide Hydrolase in Untreated Patients With Psychosis. <i>Biological Psychiatry</i> , 2020, 88, 727-735.	1.3	18
92	Quantitative imaging of neuroinflammation in human white matter: A positron emission tomography study with translocator protein 18 kDa radioligand, [¹⁸ F]â€¢FEPPA. <i>Synapse</i> , 2014, 68, 536-547.	1.2	17
93	TSPO expression and brain structure in the psychosis spectrum. <i>Brain, Behavior, and Immunity</i> , 2018, 74, 79-85.	4.1	17
94	Whole-Body Radiation Dosimetry of ¹¹ C-Carbonyl-URB694: A PET Tracer for Fatty Acid Amide Hydrolase. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1993-1997.	5.0	15
95	Epidemiology and Management of Apathy in Patients with Alzheimer's Disease. <i>Drugs and Aging</i> , 2007, 24, 547-554.	2.7	14
96	Stress precedes negative symptom exacerbations in clinical high risk and early psychosis: A time-lagged experience sampling study. <i>Schizophrenia Research</i> , 2019, 210, 52-58.	2.0	14
97	Negative symptoms in the clinical high-risk state for psychosis: Connection with cognition and primacy in impacting functioning. <i>Microbial Biotechnology</i> , 2020, 14, 188-195.	1.7	14
98	Concentration, distribution, and influence of aging on the 18â€¢kDa translocator protein in human brain: Implications for brain imaging studies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 1061-1076.	4.3	13
99	Lower amygdala fatty acid amide hydrolase in violent offenders with antisocial personality disorder: an [¹¹ C]CURB positron emission tomography study. <i>Translational Psychiatry</i> , 2021, 11, 57.	4.8	13
100	Genetically Predicted Brain C4A Expression Is Associated With TSPO and Hippocampal Morphology. <i>Biological Psychiatry</i> , 2021, 90, 652-660.	1.3	12
101	Maladaptive personality traits in patients identified at lower-risk and higher-risk for psychosis. <i>Psychiatry Research</i> , 2018, 268, 348-353.	3.3	11
102	N400 event-related brain potential evidence for semantic priming deficits in persons at clinical high risk for psychosis. <i>Schizophrenia Research</i> , 2019, 204, 434-436.	2.0	11
103	Image Derived Input Function for [¹⁸ F]-FEPPA: Application to Quantify Translocator Protein (18 kDa) in the Human Brain. <i>PLoS ONE</i> , 2014, 9, e115768.	2.5	11
104	Voxel-Based Imaging of Translocator Protein 18Kda (TSPO) in High-Resolution PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 348-350.	4.3	10
105	Inhibition of fatty acid amide hydrolase by BIA 10-2474 in rat brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 3635-3639.	4.3	10
106	Microglia imaging in methamphetamine use disorder: a positron emission tomography study with the 18 kDa translocator protein radioligand [¹⁸ F]â€¢FEPPA. <i>Addiction Biology</i> , 2021, 26, e12876.	2.6	10
107	In vivo imaging translocator protein (TSPO) in autism spectrum disorder. <i>Neuropsychopharmacology</i> , 2022, 47, 1421-1427.	5.4	10
108	Amyloid deposition in semantic dementia: a positron emission tomography study. <i>International Journal of Geriatric Psychiatry</i> , 2016, 31, 1064-1074.	2.7	9

#	ARTICLE	IF	CITATIONS
109	Normal glutathione levels in autopsied brain of chronic users of heroin and of cocaine. <i>Drug and Alcohol Dependence</i> , 2018, 190, 20-28.	3.2	9
110	Stress-induced cortical dopamine response is altered in subjects at clinical high risk for psychosis using cannabis. <i>Addiction Biology</i> , 2020, 25, e12812.	2.6	9
111	Advances in PET analyses of stress and dopamine. <i>Neuropsychopharmacology</i> , 2010, 35, 348-349.	5.4	8
112	Preliminary data indicating a connection between stress-induced prefrontal dopamine release and hippocampal TSPO expression in the psychosis spectrum. <i>Schizophrenia Research</i> , 2019, 213, 80-86.	2.0	8
113	Biodistribution and Radiation Dosimetry of the Serotonin 5-HT ₆ Ligand [11C]GSK215083 Determined from Human Whole-Body PET. <i>Molecular Imaging and Biology</i> , 2012, 14, 517-521.	2.6	7
114	Evidence That Cannabis Exposure, Abuse, and Dependence Are Related to Glutamate Metabolism and Glial Function in the Anterior Cingulate Cortex: A 1H-Magnetic Resonance Spectroscopy Study. <i>Frontiers in Psychiatry</i> , 2020, 11, 764.	2.6	7
115	Decreased Gamma Auditory Steady-State Response Is Associated With Impaired Real-World Functioning in Unmedicated Patients at Clinical High Risk for Psychosis. <i>Clinical EEG and Neuroscience</i> , 2021, 52, 400-405.	1.7	7
116	Neuropsychological Correlates of Normal Variation in Emotional Response to Visual Stimuli. <i>Journal of Nervous and Mental Disease</i> , 2007, 195, 112-118.	1.0	6
117	Using molecular imaging to understand early schizophrenia-related psychosis neurochemistry: a review of human studies. <i>International Review of Psychiatry</i> , 2017, 29, 555-566.	2.8	6
118	Validating mitochondrial electron transport chain content in individuals at clinical high risk for psychosis. <i>Scientific Reports</i> , 2019, 9, 12695.	3.3	6
119	N400 event-related brain potential as an index of real-world and neurocognitive function in patients at clinical high risk for schizophrenia. <i>Microbial Biotechnology</i> , 2021, 15, 68-75.	1.7	6
120	Cerebrovascular and microglial states are not altered by functional neuroinflammatory gene variant. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2016, 36, 819-830.	4.3	5
121	Towards an Integrated View of Early Molecular Changes Underlying Vulnerability to Social Stress in Psychosis. <i>Modern Problems of Pharmacopsychiatry</i> , 2017, 31, 96-106.	2.5	5
122	<sc>N400</sc> event-related brain potential and functional outcome in persons at clinical high risk for psychosis: A longitudinal study. <i>Psychiatry and Clinical Neurosciences</i> , 2022, 76, 114-121.	1.8	5
123	Voxel level quantification of [11C]CURB, a radioligand for Fatty Acid Amide Hydrolase, using high resolution positron emission tomography. <i>PLoS ONE</i> , 2018, 13, e0192410.	2.5	3
124	Serum lipid analysis and isotopic enrichment is suggestive of greater lipogenesis in young long-term cannabis users: A secondary analysis of a case-control study. <i>Lipids</i> , 2022, 57, 125-140.	1.7	3
125	High stress, low resilience in people at clinical high risk for psychosis: Should we consider a strengths-based approach?. <i>Canadian Psychology</i> , 2015, 56, 332-347.	2.1	2
126	Prefrontal cortical dopamine release in clinical high risk for psychosis during a cognitive task: a [11C]FLB457 positron emission tomography study. <i>European Neuropsychopharmacology</i> , 2019, 29, 1023-1032.	0.7	2

#	ARTICLE	IF	CITATIONS
127	Whole-Body Distribution and Radiation Dosimetry of ¹¹ C-(+)-PHNO, a D _{2/3} Agonist Ligand. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1802-1806.	5.0	1
128	F209. Semantic Processing Abnormalities and Their Relationship to Symptoms in Persons at Clinical High Risk for Schizophrenia: An Event-Related Brain Potential Study. <i>Biological Psychiatry</i> , 2018, 83, S320.	1.3	1
129	Personality traits in psychosis and psychosis risk linked to TSPO expression: a neuroimmune marker. <i>Personality Neuroscience</i> , 2020, 3, e14.	1.6	1
130	Identifying Electroencephalography Biomarkers in Individuals at Clinical High Risk for Psychosis in an International Multi-Site Study. <i>Frontiers in Psychiatry</i> , 2022, 13, 828376.	2.6	1
131	Increased Metaphor Production in Open-Ended Speech Samples of Patients With Prodromal and Developed Schizophrenia Detected with NLP. <i>Biological Psychiatry</i> , 2022, 91, S50.	1.3	1
132	Management of post-stroke depression. , 0, , 107-115.		0
133	PIB-Positive PET in Individuals with Early- but Not Late-Onset Frontotemporal Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, S81-S82.	1.2	0
134	Imaging neuroinflammation in schizophrenia and depression with PET. <i>European Neuropsychopharmacology</i> , 2016, 26, S134.	0.7	0
135	191. Semantic Priming Deficits in Persons at Clinical High Risk for Schizophrenia: Evidence from Event-Related Brain Potentials. <i>Biological Psychiatry</i> , 2017, 81, S79.	1.3	0
136	Stress Response in Cannabis Users and Psychosis. , 2017, , 278-287.		0
137	F134. Association of Neuroinflammation With Duration of Untreated Major Depressive Disorder. <i>Biological Psychiatry</i> , 2019, 85, S265.	1.3	0
138	Money talksâ€”Philanthropists can foster gender and racial equity. <i>EBioMedicine</i> , 2019, 49, 23.	6.1	0
139	Investigating Nociceptin/Orphanin Fq (N/OFQ) Function via Nop Receptor in Cannabis Users. <i>Biological Psychiatry</i> , 2020, 87, S81.	1.3	0
140	Imaging Nociceptin Receptor Expression in First Episode Psychosis (FEP) Using Positron Emission Tomography With the Novel Ligand [11C] NOP-1A. <i>Biological Psychiatry</i> , 2020, 87, S184.	1.3	0
141	TSPO Imaging in Psychiatric Disorders. , 2021, , 589-606.		0
142	P473. Estimating Self-Disturbance in Psychosis and Its Risk States Using Natural Language Processing Analysis of Open-Ended Interviews. <i>Biological Psychiatry</i> , 2022, 91, S280.	1.3	0
143	P556. N400 Event-Related Brain Potential as a Predictor of Symptomatic Outcome in Persons at Clinical High Risk for Psychosis. <i>Biological Psychiatry</i> , 2022, 91, S314.	1.3	0